Researcher profile
Amir Englund
Affiliations
Organizations
Public evidence
8 connected articles
Changes in cannabis potency and cannabis-related psychiatric harms: a 23-year ecological study in Denmark.2026 · Europe PMCDoes cannabidiol reduce the adverse effects of cannabis in schizophrenia? A randomised, double-blind, cross-over trial.2025 · Europe PMCExploring the relationship between frequent cannabis use, belief updating under uncertainty and psychotic-like symptoms.2024 · Europe PMCCannabidiol does not attenuate acute delta-9-tetrahydrocannabinol-induced attentional bias in healthy volunteers: A randomised, double-blind, cross-over study.2024 · Europe PMCThe acute effects of cannabis with and without cannabidiol in adults and adolescents: A randomised, double-blind, placebo-controlled, crossover experiment.2023 · PubMed Central Open AccessDoes cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios.2023 · Europe PMCCan cannabis kill? Characteristics of deaths following cannabis use in England (1998-2020).2022 · Europe PMCThe International Cannabis Toolkit (iCannToolkit): a multidisciplinary expert consensus on minimum standards for measuring cannabis use.2021 · PubMed Central Open Access
Registered research
Connected studies
Do Adolescents and Adults Differ in Their Acute Subjective, Behavioural and Neural Responses to Cannabis, With and Without Cannabidiol?nct04851392Does Cannabidiol Attenuate the Acute Effects of ∆9-tetrahydrocannabinol Intoxication in Individuals Diagnosed With Schizophrenia? A Double-blind, Randomised, Placebo-controlled Experimental Studynct04605393Reducing the Harmful Effects of Cannabis Use: Finding the Optimal CBD:THC Rationct05170217
Matched by exact identifiers only. Profile data: ORCID. Last retrieved 09/09/2026.